|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
TFCP2 can also act as a tumor suppressor, for example, it inhibits melanoma growth.
|
29410248 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer.
|
29410248 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
For example, there are numerous parallels between placental development and cancer growth; therefore, investigating the roles of TFCP2, TFCP2L1, and UBP1 in the placenta may help us better understand their functioning in cancer, as is evidenced by the studies of various other proteins and pathways.
|
30241344 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Here, we show that TFCP2 is required for YAP-dependent transcription and liver malignancy.
|
29091762 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Finally, several genes co-regulated by YAP and TFCP2 that contribute to YAP-dependent tumorigenesis are identified and verified.
|
29091762 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Here, we show that TFCP2 is required for YAP-dependent transcription and liver malignancy.
|
29091762 |
2017 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The transcription factor LSF is highly expressed in hepatocellular carcinoma (HCC) and promotes oncogenesis.
|
27845898 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Transcriptome analysis showed that alteration of TFCP2 in HCC cells led to change of genes in biological functions involved in cancer, cellular growth and proliferation, angiogenesis, cell movement and attachment.
|
25609232 |
2015 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Transcriptome analysis showed that alteration of TFCP2 in HCC cells led to change of genes in biological functions involved in cancer, cellular growth and proliferation, angiogenesis, cell movement and attachment.
|
25609232 |
2015 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
High LSF expression in CRC correlated with large tumor size, advanced pN stage, advanced AJCC stage and high Ki-67 index (P < 0.001).
|
25337247 |
2014 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
LSF is an important mediator in CRC tumorigenesis and progression, and LSF expression is an important index for and prognostic prediction.
|
25337247 |
2014 |
|
Rhabdomyosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Altogether, our data confirm and expand the spectrum of the new family of FET-TFCP2 rhabdomyosarcomas, which are associated with a predilection for the craniofacial bones, an aggressive course, and recurrent pathological features.
|
31383960 |
2020 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
The results showed MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) expression were associated with some clinical features in patients, such as pathological differentiation, tumor size, clinical stage, lymph node metastasis and distant metastasis.
|
31126819 |
2019 |
|
Rhabdomyosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Recently 2 studies reported 4 cases of primary intraosseous RMS with EWSR1/FUS-TFCP2 gene fusions, associated with somewhat conflicting histologic features, ranging from spindle to epithelioid.
|
30720533 |
2019 |
|
Rhabdomyosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Spindle cell rhabdomyosarcomas carrying the FUS-TFCP2 fusion are very rare rhabdomyosarcoma variants with osseous predilection.
|
29758589 |
2018 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Over-expression of TFCP2 promoted the growth, migration, invasion and colony formation of pancreatic cancer cells, while knocking down the expression of TFCP2 inhibited the growth, migration, invasion, colony formation and metastasis of pancreatic cancer cells.
|
29050300 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
A quest for TFCP2-regulated factors contributing to metastasis, by integration of transcriptome and ChIP on chip assay, identified fibronectin 1 (FN1) and tight junction protein 1 (TJP1) as targets of TFCP2, and as key mediators of HCC metastasis.
|
25609232 |
2015 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
After diverse bioinformatics and statistical analyses, we obtained gene expression profiles of 1,016 BRCA samples from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database, and constructed a prognostic signature, which is composed of four PCGs (TFCP2, LRRC75B, PROSER2, and STOML1) and one lncRNA (AL355592.1).
|
30950057 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
After diverse bioinformatics and statistical analyses, we obtained gene expression profiles of 1,016 BRCA samples from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database, and constructed a prognostic signature, which is composed of four PCGs (TFCP2, LRRC75B, PROSER2, and STOML1) and one lncRNA (AL355592.1).
|
30950057 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer.
|
29410248 |
2018 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer.
|
29410248 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer.
|
29410248 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer.
|
29410248 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Western blot, colony formation assay, migration and invasion experiment were performed to investigate the effects of TFCP2 on the growth and migration of pancreatic cancer cells.
|
29050300 |
2017 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High LSF expression in CRC correlated with large tumor size, advanced pN stage, advanced AJCC stage and high Ki-67 index (P < 0.001).
|
25337247 |
2014 |